Search Results
Your search for ASCO,ASCO matches 20815 pages
Showing 401 - 450Metastatic NSCLC Survival Rates in the Immunotherapy Era
The survival rates of patients with advanced non–small cell lung cancer (NSCLC) have improved since the introduction of the first immunotherapeutic in this population in the United States in 2015, according to a recent study published by Wang et al in Cancer. NSCLC accounts for up to 90% of all...
FDA Approves IDH1/2 Inhibitor for Certain Patients With Astrocytoma or Oligodendroglioma
The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo), an isocitrate dehydrogenase-1 (IDH1) and -2 (IDH2) inhibitor, for adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following...
Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer
Nasopharyngeal carcinoma is a rare and aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific, data from the International...
Active Surveillance May Enable Patients With Esophageal Cancer to Delay or Avoid Surgery
Although esophageal cancer in the United States is relatively rare—affecting about 22,400 people each year and making up about 1% of all cancer cases—the disease is common in East and Central Asian countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous cell ...
Selpercatinib in East Asian Patients With RET Fusion–Positive NSCLC: LIBRETTO-431
Lung cancer is the leading cause of cancer-related death worldwide, accounting for the highest mortality rates among both men and women. Most lung cancers—between 80% and 85%—are non–small cell lung cancer (NSCLC), and between 1% and 2% of patients are diagnosed with RET-altered NSCLC. The results...
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.1...
Should Low-Dose CT Screening Be Recommended for Those at Low Risk for Lung Cancer?
Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose computed tomography (CT) screening an essential component in the fight against lung cancer. Recent studies, particularly from...
Daily E-Cigarette Use May Be Linked to Higher Combustible Cigarette Cessation
U.S. adults who use e-cigarettes daily and smoke combustible cigarettes may be more likely to quit smoking traditional cigarettes compared with those who smoke but use e-cigarettes less frequently, according to a recent study published by Kasza et al in JAMA Network Open. The findings suggest that...
Investigating Fungal Bloodstream Infections in Bone Marrow Transplant Recipients
Researchers may have uncovered the mechanisms behind fungal bloodstream infections in patients who receive bone marrow transplants, according to a recent study published by Zhai et al in Nature Medicine. Background A phenomenon known as heteroresistance occurs when a tiny fraction of bacteria...
Common Blood Tests May Improve Early Cancer Diagnosis
The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...
FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma
On August 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have ...
Novel AI Tool May Predict Risk of Chronic Pain in Patients With Breast Cancer
A novel artificial intelligence (AI) model may prove to be effective at predicting which patients with breast cancer are likely to develop chronic pain, according to a recent study published by Park et al in the Journal of Nursing Scholarship. The findings may help physicians to better understand...
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly With Chemotherapy
On August 1, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adults with primary advanced or recurrent endometrial cancer. Dostarlimab was previously approved in July 2023 with carboplatin...
Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A novel treatment regimen with the bispecific antibody glofitamab has demonstrated improvements in survival outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data presented at the European Hematology Association (EHA) 2024 Congress.1 The phase III ...
Liver Transplantation vs Standard Therapies in Patients With Colorectal Cancer Liver Metastasis
Certain patients with colorectal cancer that has metastasized to the liver may experience improved progression-free survival with liver transplantation compared with standard therapies, according to a recent study published by Byrne et al in JAMA Surgery. Background Colorectal cancer often...
Education Level, Social Media Awareness May Be Linked to Cancer Fatalism
Investigators have found that patients with a lower level of education and social media awareness may hold more fatalistic beliefs about cancer compared with those who are more skilled at finding information through social media, according to a recent study published by Stimpson et al in Cancer...
New Report Shows Vaping and Smoking Together Increases Lung Cancer Risk Fourfold Compared to Smoking Alone
People who use e-cigarettes in conjunction with cigarette smoking are four times more likely to develop lung cancer than people who just smoke cigarettes, according to new study published by Harris et al the Journal of Oncology Research and Therapy. These findings were consistent across gender and...
Gynecologic Oncologist Lynette Ann Denny, MD, PhD, Dies at Age 66
The global oncology and public health communities are mourning the death of Lynette Ann Denny, MD, PhD, a world-renowned gynecologic oncologist and a leading researcher in the prevention of cervical cancer in low-resource settings. Dr. Denny died on June 9, 2024, in Cape Town, South Africa, of...
Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma?
The presence of a mutation in any one of three genes known to be involved in DNA damage repair may be associated with complete pathologic response to cisplatin-based neoadjuvant chemotherapy, as measured by pathologic downstaging at the time of cystectomy in patients with muscle-invasive urothelial ...
FDA Approves Daratumumab and Hyaluronidase-fihj With VRd for Multiple Myeloma
On July 30, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for...
Do Nonstatin Cholesterol-Lowering Drugs Influence the Risk of Hepatic Cancer?
Investigators examined whether nonstatin cholesterol-lowering drugs may affect the risk of hepatic cancer, according to a recent study published by Zamani et al in Cancer. Background Hepatic cancer is the sixth most common cancer type across the world and the third leading cause of cancer-related...
Making a Difference in Global Oncology
“Making a difference in global oncology means framing positive system changes. To me, Dr. Khalid El Bairi is among the global cancer researchers I know who so far has made the largest achievements. “Since the very first interaction with Khalid, what I have captured is passion for the community he...
Cancer Research and Care Beyond Borders for Global Oncologist Dario Trapani, MD
In this installment of The ASCO Post’s Living a Full Life series, I interviewed Dario Trapani, MD, a medical oncologist at the European Institute of Oncology, Milan and Assistant Professor at the Department of Oncology and Haemato-Oncology of the University of Milan, in Italy. Dr. Trapani is a...
Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma Uncovered
Researchers may have uncovered why some patients with Merkel cell carcinoma do not respond to immune checkpoint blockade therapy, according to a recent study published by Reinstein et al in Cancer Discovery. Background Merkel cell carcinoma—a rare but highly aggressive type of skin cancer—is known...
Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance
Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...
Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases
Sara A. Hurvitz, MD, FACP, of Fred Hutch Cancer Center, discusses her presentation on new therapeutic strategies for HER2-positive metastatic disease including brain metastases. Dr. Hurvitz is Senior Vice President and Director, Clinical Research Division, Fred Hutch Cancer Center, and Professor,...
Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer
On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield blood test for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for...
Is Lower-Dose Radiopharmaceutical Therapy Effective in Advanced Prostate Cancer?
Treatment with de-escalated actinium (Ac)-225–prostate-specific membrane antigen (PSMA)-617 or a combination of lutetium (Lu)-177/Ac-225–PSMA-617 resulted in similar median overall survival and prostate-specific antigen (PSA) response rates and better tolerance among patients with advanced-stage...
Risk of Breast Cancer May Be Lower Within First 10 Years Following Ovarian Cancer Diagnosis
Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...
Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer
Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...
Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors: Long-Term Outcomes
In a long-term analysis reported in the Journal of Clinical Oncology, Gleeson et al found that initial salvage treatment for germ cell tumors with paclitaxel, ifosfamide, and cisplatin (TIP) was associated with positive long-term outcomes in both favorable- and unfavorable-risk disease. Study...
New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma
The advancement of retinoblastoma treatment over the past 15 years may have resulted in a higher likelihood of vision preservation without compromising survival, according to a recent study presented by Kocharian et al at the Society of NeuroInterventional Surgery (SNIS) Annual Meeting 2024 and...
Cancer Risk From Exposure to Pesticides May Be Comparable to Risk From Smoking, Study Finds
Agricultural pesticides may carry a similar risk as smoking for some types of cancers, according to a recent study published by Gerken et al in Frontiers in Cancer Control and Society. Background In modern agriculture practices, pesticides are essential to ensure high enough crop yields and food...
Introducing ‘Conexiant’
The publisher and editorial staff of The ASCO Post are happy to share an exciting announcement. While our company was formerly known as Harborside, powered by BroadcastMed, earlier this summer we announced a new name and platform for our business, Conexiant. Importantly, we continue our essential...
Cancer and Fatherhood: A Story of Personal Power in the Face of a Mortal Disease
Iron Dad: A Cancer Survivor’s Story of Discovering Strength, Life, and Love Through Fatherhood by Paul Weigel is an inspiring and deeply moving memoir that transcends the traditional boundaries of parenthood and personal transformation. This story begins with a sense of discontent and a desire for...
Phase II Study Shows Activity for Novel Targeted Agent in KRAS G12C–Mutated NSCLC
The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...
Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions
A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...
Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting
The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in...
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoadjuvant chemoradiotherapy CROSS regimen. The results were presented during the Plenary Session of...
Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology
When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...
Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...
Eliminating Racial Disparities in Colorectal Cancer Screening
Eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States, according to a recent study published by Alagoz et al in the Journal of the National Cancer Institute. Background Although both the ...
Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment
Kristin Rojas, MD, FACS, of the University of Miami, shares key points from her discussion on improving sexual health during breast cancer treatment. Dr. Rojas is an Associate Professor of Surgery in the DeWitt Daughtry Family Department of Surgery, Division of Surgery, Miller School of Medicine at ...
Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?
Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology...
Novel Target Identified for Treating HTLV-1–Associated Diseases
Blocking the tyrosine kinase KDR could lead to cell death caused by the degradation of the TAX viral protein, thereby treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1), according to a recent study published by Mohanty et al in Nature Communications. Background HTLV-1 is...
AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...
Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates
Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and...
Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research...
